FDA Grants Accelerated Approval to T-DXd in Advanced HER2+ Solid Tumors
Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.
Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.
On May 15, 2024, the FDA granted accelerated approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adults with follicular lymphoma.
Drugmakers are expanding their attack on KRAS mutations, with clinical trials now underway for therapies targeting the common G12D variant, as well as broader pan-RAS…
Fuzuloparib, with or without apatinib, improved PFS over chemotherapy in patients with previously treated, HER2-negative, BRCA-mutated breast cancer.
A retrospective analysis determined the association between various adverse effects and overall and progression-free survival in patients with HCC receiving atezolizumab plus bevacizumab.
More than 150 team members will staff the new facility when it opens in January.
Atezolizumab plus chemotherapy did not improve OS vs chemotherapy alone in select patients with early relapsing triple-negative breast cancer.
Sangeetha Venugopal, MD, MS, provides an overview of how patients with blastic plasmacytoid dendritic cell neoplasms (BPDCN) are diagnosed.
Targeted Oncology spoke with Howard D. Edington, MD, about the advancements in engineering oncolytic viruses to be able to target specific cancers and various combination…
An abstract is unavailable.